Abstract
Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that have not responded to analgesics can be treated with triptans, which are drugs specific for migraine treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation training. Medications for the prevention of migraines have also been developed since they are more affective in offsetting the symptoms. Ubrogepant’s high specificity and selectivity for calcitonin gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the treatment of migraines with or without aura due to their decreased selectivity. The most frequently reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults.
Highlights
This study found that at 100 mg and 200 mg was shown to be generally well tolerated and efficacious for acute migraine treatment over a 1-year period [39]
A study by Goldstein et al found that nonprescription medications were first used by more than fifty percent of patients in an attempt to treat their migraines before they visited a physician due to unsuccessful treatment [40]
Stress management is the traditional focus of Cognitive behavioral therapy (CBT), while behavioral interventions, mindfulness, and meditation are directed towards treatment for comorbidities [41,42]
Summary
Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States [1,2,3] It is a recurring and disabling condition that can cause a reduction in the quality of life including the ability to work or participate in social activities [1,4]. The aura phase may precede a headache, but it only presents in around 30% of patients experiencing migraine [1,2,5]. Ubrogepant is prescribed to adult patients for acute migraine therapy with or without aura for acute, abortive treatment. It is not indicated as a preventative treatment [3,21,22]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
